ERBB2 and breast carcinoma: An important study was carried out to observe the effects of epigallocatechin-3 gallate (EGCG) on HER2/neu-overexpressing breast cancer cells and results demonstrated that EGCG reduced signaling through the phosphatidylinositol 3-kinase, Akt kinase to NF-kappaB pathway because of inhibition of basal HER2/neu receptor tyrosine phosphorylation [51].